DBS for Obsessive-Compulsive Disorder

NARecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 6, 2024

Primary Completion Date

January 1, 2030

Study Completion Date

January 1, 2030

Conditions
Obsessive-Compulsive Disorder (OCD)
Interventions
DEVICE

Reclaim™ DBS Therapy

DBS is indicated for bilateral stimulation of the ventral anterior limb of the internal capsule as an adjunct to medications and as an alternative to anterior capsulotomy for treatment of chronic, severe, treatment-resistant obsessive compulsive disorder (OCD) in adult patients who have failed at least three selective serotonin reuptake inhibitors (SSRIs). Medtronic received humanitarian device exemption (HDE) approval for Reclaim DBS Therapy for the management of OCD on February 19, 2009.

Trial Locations (1)

11004

RECRUITING

Zucker Hillside Hospital, Queens

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Medtronic

INDUSTRY

lead

Northwell Health

OTHER